References of "Gathon, Henry-Jean"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailZones d'activité économique en Wallonie : quelles retombées fiscales pour les communes ?
Xhignesse, Guillaume ULg; Bianchet, Bruno ULg; Bourgeois, Marc ULg et al

in Revue de Fiscalité Régionale et Locale (2013), 2

Les zones d'activité économique constituent, en Wallonie, un des leviers majeurs à disposition du Gouvernement pour favoriser le développement économique. Leur implantation suscite toutefois de nombreux ... [more ▼]

Les zones d'activité économique constituent, en Wallonie, un des leviers majeurs à disposition du Gouvernement pour favoriser le développement économique. Leur implantation suscite toutefois de nombreux débats au sein des élus locaux. Ces débats sont notamment alimentés par la perception que ces zones génèrent des recettes fiscales très limitées pour les communes. Cette contribution propose une analyse et une mesure des facteurs qui influencent ces recettes et, par conséquent, les choix locaux en matière d'affectation de l'espace. [less ▲]

Detailed reference viewed: 169 (113 ULg)
Full Text
See detailAnalyse des retombées des zones d'activité économique au niveau communal
Bianchet, Bruno ULg; Xhignesse, Guillaume ULg; Gathon, Henry-Jean ULg et al

Report (2012)

La création d’une zone d’activité économique sur le territoire d’une commune engendre des conséquences et des retombées pour cette dernière. Toutefois, certaines communes seraient de moins en moins ... [more ▼]

La création d’une zone d’activité économique sur le territoire d’une commune engendre des conséquences et des retombées pour cette dernière. Toutefois, certaines communes seraient de moins en moins favorables à accueillir des activités économiques sur leur territoire. L’objectif de cette expertise est de faire l’état des lieux de la question permettant ainsi d’évaluer les principaux impacts issus de l’accueil d’activités économiques, ainsi que de formuler des propositions en vue d’inciter les communes à accueillir ou développer, sur leur territoire, de nouveaux espaces dédiés à l’activité économique. [less ▲]

Detailed reference viewed: 153 (44 ULg)
Full Text
See detailIdentification du potentiel territorial permettant le développement de nouveaux projets le long du réseau wallon des voies navigables
Teller, Jacques ULg; Gathon, Henry-Jean ULg; Rigo, Philippe ULg et al

Report (2011)

Cette expertise porte sur une mission d'étude visant à établir un cadastre du potentiel territorial permettant le développement de nouveaux projets en relation avec le réseau des voies navigables de ... [more ▼]

Cette expertise porte sur une mission d'étude visant à établir un cadastre du potentiel territorial permettant le développement de nouveaux projets en relation avec le réseau des voies navigables de Wallonie et ainsi à la positionner en tant que point charnière entre les régions belges, les Pays-Bas, la France et l'Allemagne par le transport par voie d'eau. Ce travail consiste en l'établissement d'un inventaire des zones portuaires actuellement exploitées et d'une cartographie des nouvelles zones portuaires potentielles [less ▲]

Detailed reference viewed: 168 (61 ULg)
Full Text
Peer Reviewed
See detailHospitalisation costs of hip fractures in Belgium
Hiligsmann, Mickaël ULg; Gathon, Henry-Jean ULg; Bruyère, Olivier ULg et al

in Osteoporosis International (2011, March), 22(Suppl.1), 332

Detailed reference viewed: 28 (7 ULg)
Full Text
Peer Reviewed
See detailPatient out-of-pocket contributions related to hip fracture hospital costs in Belgium
Hiligsmann, Mickaël ULg; Gathon, Henry-Jean ULg; Bruyère, Olivier ULg et al

in Osteoporosis International (2011, March), 22(Suppl.1), 333

Detailed reference viewed: 43 (23 ULg)
Full Text
Peer Reviewed
See detailPotential Clinical and Economic Impact of Nonadherence with Osteoporosis Medications.
Hiligsmann, Mickaël ULg; Rabenda, Véronique ULg; Gathon, Henry-Jean ULg et al

in Calcified Tissue International (2010), 86

This study aims to estimate the potential clinical and economic implications of therapeutic adherence to bisphosphonate therapy. A validated Markov microsimulation model was used to estimate the impact of ... [more ▼]

This study aims to estimate the potential clinical and economic implications of therapeutic adherence to bisphosphonate therapy. A validated Markov microsimulation model was used to estimate the impact of varying adherence to bisphosphonate therapy on outcomes (the number of fractures and the quality-adjusted life-years [QALYs]), health-care costs, and the cost-effectiveness of therapy compared with no treatment. Adherence was divided into persistence and compliance, and multiple scenarios were considered for both concepts. Analyses were performed for women aged 65 years with a bone mineral density T-score of -2.5. Health outcomes and the cost-effectiveness of therapy improved significantly with increasing compliance and/or persistence. In the case of real-world persistence and with a medical possession ratio (MPR; i.e., the number of doses taken divided by the number of doses prescribed) of 100%, the QALY gain and the number of fractures prevented represented only 48 and 42% of the values estimated assuming full persistence, respectively. These proportions fell to 27 and 23% with an MPR value of 80%. The costs per QALY gained, for branded bisphosphonates (and generic alendronate), were estimated at <euro>19,069 (<euro>4,871), <euro>32,278 (<euro>11,985), and <euro>64,052 (<euro>30,181) for MPR values of 100, 80, and 60%, respectively, assuming real-world persistence. These values were <euro>16,997 (<euro>2,215), <euro>24,401 (<euro>6,179), and <euro>51,750 (<euro>20,569), respectively, assuming full persistence. In conclusion, poor compliance and failure to persist with osteoporosis medications results not only in deteriorating health outcomes, but also in a decreased cost-effectiveness of drug therapy. Adherence therefore remains an important challenge for health-care professionals treating osteoporosis. [less ▲]

Detailed reference viewed: 38 (8 ULg)
Full Text
Peer Reviewed
See detailCost-Effectiveness of Osteoporosis Screening Followed by Treatment: The Impact of Medication Adherence.
Hiligsmann, Mickaël ULg; Gathon, Henry-Jean ULg; Bruyère, Olivier ULg et al

in Value in Health (2010), 13(4), 394-401

ABSTRACT Objective: To estimate the impact of medication adherence on the cost-effectiveness of mass-screening by bone densitometry followed by alendronate therapy for women diagnosed with osteoporosis ... [more ▼]

ABSTRACT Objective: To estimate the impact of medication adherence on the cost-effectiveness of mass-screening by bone densitometry followed by alendronate therapy for women diagnosed with osteoporosis. Methods: A validated Markov microsimulation model with a Belgian health-care payer perspective and a lifetime horizon was used to assess the cost per quality-adjusted life year (QALY) gained of the screening/treatment strategy compared with no intervention. Real-world adherence to alendronate therapy and full adherence over 5 years were both investigated. The real-world adherence scenario employed adherence data from published observational studies, and medication adherence was divided into persistence, compliance, and primary adherence. Uncertainty was investigated using one-way and probabilistic sensitivity analyses. Results: At 65 years of age, the costs per QALY gained because of the screening/treatment strategy versus no intervention are euro32,008 and euro16,918 in the real-world adherence and full adherence scenarios, respectively. The equivalent values are euro80,836 and euro40,462 at the age of 55 years, and they decrease to euro10,600 and euro1229 at the age of 75 years. Sensitivity analyses show that the presence of the upfront cost of case finding has a substantial role in the impact of medication adherence on cost-effectiveness. Conclusion: This study indicates that nonadherence with osteoporosis medications substantially increases the incremental cost-effectiveness ratio of osteoporosis screening strategies. All aspects of medication adherence (i.e., compliance, persistence, and primary adherence) should therefore be reported and included in pharmacoeconomic analyses, and especially in the presence of the upfront cost of case finding (such as screening cost). [less ▲]

Detailed reference viewed: 74 (22 ULg)
Full Text
See detailLes services d'intérêt économique général en Europe : Le cas de la gestion des déchets en Belgique
Gathon, Henry-Jean ULg; Collignon, Aubry ULg

Scientific conference (2009, November)

Waste management in Belgium, 2008 - 2009.

Detailed reference viewed: 44 (9 ULg)
Full Text
Peer Reviewed
See detailLes services d'intérêt économique général en Europe : Le cas de la gestion de l'eau en Belgique
Gathon, Henry-Jean ULg; Collignon, Aubry ULg

Conference (2009, April)

Le secteur de l'eau en Belgique, production, distribution, traitement des eaux usées.

Detailed reference viewed: 97 (23 ULg)
Full Text
Peer Reviewed
See detailClinical en economic implications of non-adherence with osteoporosis medications
Hiligsmann, Mickaël ULg; Rabenda, Véronique ULg; Gathon, Henry-Jean ULg et al

in Osteoporosis International (2009, March), 20(S1), 16

Detailed reference viewed: 31 (6 ULg)
Full Text
Peer Reviewed
See detailDevelopment and Validation of a Markov Microsimulation Model for the Economic Evaluation of Treatments in Osteoporosis.
Hiligsmann, Mickaël ULg; Ethgen, Olivier ULg; Bruyère, Olivier ULg et al

in Value in Health (2009), 12(5), 687-696

ABSTRACT Objective: Markov models are increasingly used in economic evaluations of treatments for osteoporosis. Most of the existing evaluations are cohort-based Markov models missing comprehensive memory ... [more ▼]

ABSTRACT Objective: Markov models are increasingly used in economic evaluations of treatments for osteoporosis. Most of the existing evaluations are cohort-based Markov models missing comprehensive memory management and versatility. In this article, we describe and validate an original Markov microsimulation model to accurately assess the cost-effectiveness of prevention and treatment of osteoporosis. Methods: We developed a Markov microsimulation model with a lifetime horizon and a direct health-care cost perspective. The patient history was recorded and was used in calculations of transition probabilities, utilities, and costs. To test the internal consistency of the model, we carried out an example calculation for alendronate therapy. Then, external consistency was investigated by comparing absolute lifetime risk of fracture estimates with epidemiologic data. Results: For women at age 70 years, with a twofold increase in the fracture risk of the average population, the costs per quality-adjusted life-year gained for alendronate therapy versus no treatment were estimated at Euro 9105 and Euro 15,325, respectively, under full and realistic adherence assumptions. All the sensitivity analyses in terms of model parameters and modeling assumptions were coherent with expected conclusions and absolute lifetime risk of fracture estimates were within the range of previous estimates, which confirmed both internal and external consistency of the model. Conclusion: Microsimulation models present some major advantages over cohort-based models, increasing the reliability of the results and being largely compatible with the existing state of the art, evidence-based literature. The developed model appears to be a valid model for use in economic evaluations in osteoporosis. [less ▲]

Detailed reference viewed: 223 (32 ULg)
Full Text
Peer Reviewed
See detailImpact of medication non-compliance and non-persistence on pharmacoeconomic evaluations in osteoporosis
Hiligsmann, Mickaël ULg; Rabenda, Véronique ULg; Gathon, Henry-Jean ULg et al

in Osteoporosis International (2008, December), 19(S2), 282

Detailed reference viewed: 34 (13 ULg)
Full Text
See detailLes finances et la fiscalité des provinces wallonnes
Abada, Maya ULg; Collignon, Aubry ULg; Durviaux, Ann-Lawrence ULg et al

Report (2008)

Les finances et la fiscalité des provinces wallonnes, de 2001 à 2007 et projections.

Detailed reference viewed: 303 (69 ULg)
Full Text
Peer Reviewed
See detailLifetime absolute risk of hip and other osteoporotic fracture in Belgian women.
Hiligsmann, Mickaël ULg; Bruyère, Olivier ULg; Ethgen, Olivier ULg et al

in BONE (2008), 43(6), 991-4

OBJECTIVES: To estimate the lifetime absolute risks of hip and other osteoporotic fracture in Belgian women aged 60 years and to examine the effect of changes in baseline population fracture risk and ... [more ▼]

OBJECTIVES: To estimate the lifetime absolute risks of hip and other osteoporotic fracture in Belgian women aged 60 years and to examine the effect of changes in baseline population fracture risk and changes in life expectancy. MATERIALS AND METHODS: Estimates were performed using a Markov microsimulation model and were based on the incidence of first fracture as well as life expectancy. Baseline scenario included projected mortality rates and increasing fracture incidence by 1% per year. Alternative scenarios were performed on age, life expectancy and trends in fracture incidence. Lifetime fracture risk for osteoporotic population (T-score <or= -2.5) was also estimated. RESULTS: In the baseline scenario, lifetime absolute risks of hip fracture and of any major osteoporotic fracture (hip, clinical vertebral or wrist) were respectively 24.8% and 44.3%. Alternative scenarios showed that when assuming no change of age-specific fracture rates over time, these lifetime risks were 18.3% and 35.2%, while these values were 20.0% and 38.3% assuming no future mortality reductions. For osteoporotic women, these values were respectively 34.5% and 51.5%. CONCLUSION: We conclude that absolute lifetime fracture risks are substantial and that trends in fracture incidence and changes in life expectancy have a marked impact on absolute lifetime fracture risks. [less ▲]

Detailed reference viewed: 45 (12 ULg)
See detailRapport de la Commission d'étude de la méthodologie utilisée dans l'analyse des transferts interrégionaux
Gathon, Henry-Jean ULg; Cattoir, Philippe; de Callatay, Etienne et al

Report (2006)

Detailed reference viewed: 13 (3 ULg)
See detailEvaluation des retombées économiques du circuit de Spa-Francorchamps
Gathon, Henry-Jean ULg; Bebermans, Olivier; Delcour, Catherine et al

Report (2006)

Detailed reference viewed: 123 (11 ULg)
Full Text
See detailReconstruire la ville sur la ville - Recyclage des espaces dégradés
De Keersmaecker, M.-L.; Denef, Julie; Harou, Raphaëlle et al

Report (2005)

Detailed reference viewed: 61 (12 ULg)